Trial Profile
A Phase II Study of Intratumoral Application of L19IL2/L19TNF in Melanoma Patients in Clinical Stage III or Stage IV M1a With Presence of Injectable Cutaneous and/or Subcutaneous Lesions
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bifikafusp alfa (Primary) ; Onfekafusp alfa (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Philogen
- 25 May 2015 Status changed from recruiting to completed according to ClinicalTrials.gov record
- 31 May 2014 The study design presented at 50th Annual Meeting of the American Society of Clinical Oncology.
- 02 May 2014 New source identified and integrated (ClinicalTrial.gov; NCT02076633)